astaxanthin, astaxanthine, E-astaxanthin
| Name | Astaxanthin | ||
| PubChem CID | 5281224 | ||
| Molecular Weight | 596.8g/mol | ||
| Synonyms |
astaxanthin, astaxanthine, E-astaxanthin |
||
| Formula | C₄₀H₅₂O₄ | ||
| SMILES | CC1=C(C(CC(C1=O)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(C(=O)C(CC2(C)C)O)C)C)C | ||
| InChI | 1S/C40H52O4/c1-27(17-13-19-29(3)21-23-33-31(5)37(43)35(41)25-39(33,7)8)15-11-12-16-28(2)18-14-20-30(4)22-24-34-32(6)38(44)36(42)26-40(34,9)10/h11-24,35-36,41-42H,25-26H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,27-15+,28-16+,29-19+,30-20+/t35-,36-/m0/s1 | ||
| InChIKey | MQZIGYBFDRPAKN-UWFIBFSHSA-N | ||
| CAS Number | 472-61-7 | ||
| ChEMBL ID | CHEMBL1255871 | ||
| ChEBI ID | CHEBI:40968 | ||
| Herb ID | HBIN017178 | ||
| Drug Bank ID | DB06543 | ||
| KEGG ID | C08580 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | YuShengHongQiuZao | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Chlorophyta
-->Class: Chlorophyceae
-->Order: Volvocales
-->Family: Haematococceae
-->Genus: Haematococcus
-->Species: Haematococcus Pluvialis
|
||
| Pair Name | Astaxanthin, Cytarabine | |||
| Partner Name | Cytarabine | |||
| Disease Info | [ICD-11: 2B33.3] | Acute lymphoblastic leukemia | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | BCL-xL | hsa598 |
| Up-regulation | Expression | CASP3 | hsa836 | |
| Up-regulation | Expression | CASP8 | hsa841 | |
| Down-regulation | Expression | IL6 | hsa3569 | |
| Down-regulation | Expression | TNF | hsa7124 | |
| Up-regulation | Expression | TP53 | hsa7157 | |
| In Vitro Model | NALM-6 | Adult B acute lymphoblastic leukemia | Homo sapiens (Human) | CVCL_0092 |
| Result | Co-treatment of ASX and Ara-C has synergism effects on apoptosis pathways, cell proliferation inhibition, and decreased inflammation. | |||
| Pair Name | Astaxanthin, Sorafenib | |||
| Partner Name | Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Inhibition-->Tumor angiogenesis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Down-regulation | Expression | BNIP3 | hsa664 | |
| Down-regulation | Expression | EGLN1 | hsa54583 | |
| Up-regulation | Expression | HIF1A | hsa3091 | |
| Down-regulation | Phosphorylation | JAK2 | hsa3717 | |
| Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
| Down-regulation | Expression | VEGFA | hsa7422 | |
| Up-regulation | Phosphorylation | VHL | hsa7428 | |
| In Vivo Model | This experiment was performed using the H22 tumor-bearing mousemodel and the Hepa1-6 tumor-bearing mouse model. | |||
| Result | Astaxanthin Augmented the Anti-Hepatocellular Carcinoma Efficacy of Sorafenib Through the Inhibition of the JAK2/STAT3 Signaling Pathway and Mitigation of Hypoxia within the Tumor Microenvironment | |||
| No. | Title | Href |
|---|---|---|
| 1 | Astaxanthin decreases the growth-inhibitory dose of cytarabine and inflammatory response in the acute lymphoblastic leukemia cell line NALM-6. Mol Biol Rep. 2022 Jul;49(7):6415-6422. doi: 10.1007/s11033-022-07452-8. | Click |
| 2 | Astaxanthin Augmented the Anti-Hepatocellular Carcinoma Efficacy of Sorafenib Through the Inhibition of the JAK2/STAT3 Signaling Pathway and Mitigation of Hypoxia within the Tumor Microenvironment. Mol Nutr Food Res. 2024 Jan;68(2):e2300569. doi: 10.1002/mnfr.202300569. | Click |
